Current drugs do not stop or reverse the progression of Alzheimer’s disease (AD).

Also, brains of AD patients show a number of biological changes and effective drugs should target those together.

Cannabidiol (CBD) has such abilities when tested in AD cell models. We found that CBD can also prevent and reverse memory deficits in AD mice. We propose to provide convincing preclinical evidence for the benefits of CBD for human AD therapy and to define mechanisms involved.

Funding body

National Health and Medical Research Council

Scheme name

Project Grants

Years funded

2018 – 2020

Lead institution

Western Sydney University